



Yash Dayal¹, Dillon Drab MD², Collin Ly DO², Blake Thompson MD², Mingyang Cui MSc¹,
Hellen Oduor MBChB¹, Parvez Mantry MD³

¹Clinical Research Institute, Methodist Health System, Dallas TX 75203

²Gastroenterology and Hepatology, Methodist Dallas Medical Center, Dallas TX 75203

³The Liver Institute, Methodist Dallas Medical Center, Dallas TX 75203

Introduction

- Nonalcoholic steatohepatitis (NASH) has now become the leading cause of liver transplants
- NASH patients are quite different than previous alcohol related cirrhosis prompting the need for further research of causes and potential therapeutic interventions
- Purpose of this study was to assess the post liver transplant cardiovascular and infection complications in NASH patients to help identify early interventions that could potentially mitigate these serious posttransplant complications.

Methods

- Single center retrospective study
- Total 124 patients who received liver transplants from January 2017-September 2022
- 67 NASH vs 57 non-NASH patients who underwent propensity matching analysis matched the disease cohorts on: MELD, age, and gender at time of transplant.
- Demographic, clinical, and transplant-related outcomes (cardiovascular event, infection, mortality) were collected at one year.
- Groups were compared using the Student's t-test, Chi
 Square Test of Independence, Fisher's exact test,
 Wilcoxon Rank-sum test, and Logistic/Cox regression.

Results

- 124 liver transplant patients (67 NASH vs. 57 non-NASH) were analyzed.
- NASH patients had significantly higher mean BMI at time of transplant (31.99 vs 28.40, p=0.0126) and at one-year post-transplant (32.95 vs. 30.10, p = 0.0126).
- Mean number of hospitalizations in one year was higher in the control cohort (1.23 vs 3.8, p = .0001) while mortality rate at one, two, and three months and 1, 3, and 5 years was not significantly different between the two cohorts.
- Similar cardiovascular outcomes were observed at one year between the NASH vs. non-NASH groups as can be seen in the MI rate (0% vs. 0%), and CVA rate (1.49% vs 3.64%, p = .588).
- Surprisingly, there were no differences in post-transplant infection rates (58.21% vs. 61.82%, p=0.686) and the types of infection were similar between the two groups.

TABLE 1		NASH	Non-NASH
BMI	At time of transplant	31.99	28.37
	1 year post transplant	32.95	30.09
Cardiovascular Complications (after 1 year)			
	Cardiovascular event	7.46%	14.81%
	MI	0.00%	0.00%
	CVA	1.49%	3.64

TABLE 2	NASH	Non- NASH
Infection Events	58.21%	61.82%
Total hospitalizations (mean)	1.23	3.8
Mortality at 1 month	2.99%	1.82%
Mortality at 2 months	0.00%	1.85%
Mortality at 3 months	0.00%	3.77%
Mortality at 1 year	2.99%	3.92%

Table 2: Comparison of NASH and non-NASH infection rate, number of hospitalizations and mortality rates

at 1,2,3 and 12 months

complications

Table 1: Comparison of NASH and

non-NASH BMI and Cardiovascular

Conclusion

- NASH patients have higher BMI at times of transplant
- Hospitalization rate lower in NASH group compared to control
- No difference in mortality nor cardiovascular/infection complications
- Study is limited by retrospective nature of analysis and limited post-transplant follow-up period limit the study.
- A thorough cardiovascular assessment and careful patient selection in patients with metabolic syndrome could explain these findings.
- Larger patient samples with a longer follow-up period will be included in future publication to further investigate the cardiovascular complications and other post-transplant complications of NASH patients.

Disclosures

No additional funding was provided for this study and authors have no conflicts to declare.